EOVIST
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
DIAGNOSTIC_NONTHERAPEUTIC_PRODUCT; canonical 2013 DEEP_REVIEW; APPROVAL_YEAR_FALLBACK.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| US6039931 | 2021-11-13 | U U-1239 | N | N | U Issued claim set covers NMR image-enhancement methods using structurally specified DTPA metal complexes, rather than standalone compound protection. Retain the diagnostic-method classification; EOVIST is excluded from the therapeutic canonical queue and no therapeutic full-label anchor is adopted. | — | — | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| NCE | 2008-07-03 | 2013-07-03 | HISTORICAL_ORIGINAL_ADULT_SCOPE; Diagnostic product remains excluded from therapeutic selection. NCE ends 2013-07-03, based on the original 2008 active-moiety approval, not five years after the 15 mL presentation approval on 2013-02-04. M-155 through 2018-03-27 adds observational pediatric study findings, age greater than 2 months through 18 years, to section 8.4; it is not protection of all adult/pediatric diagnostic use. The latest 2026 label extends pediatric evidence further. No complete later-label anchor or combination is established. | N | N | — | Source | |
| M-155 | 2015-03-27 | 2018-03-27 | PARTIAL_PEDIATRIC_OBSERVATIONAL_DATA; Diagnostic product remains excluded from therapeutic selection. NCE ends 2013-07-03, based on the original 2008 active-moiety approval, not five years after the 15 mL presentation approval on 2013-02-04. M-155 through 2018-03-27 adds observational pediatric study findings, age greater than 2 months through 18 years, to section 8.4; it is not protection of all adult/pediatric diagnostic use. The latest 2026 label extends pediatric evidence further. No complete later-label anchor or combination is established. | N | N | — | Source |
2026-10-12 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_2011_2026_REVIEWED
2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| No generic approval facts are linked to this product. | |||||||
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 0 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No final-approval records are linked to this product. | ||||||
Decision evidence (4)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2021-11-13 | FTO_TAIL | Issued claim set covers NMR image-enhancement methods using structurally specified DTPA metal complexes, rather than standalone compound protection. Retain the diagnostic-method classification; EOVIST is excluded from the therapeutic canonical queue and no therapeutic full-label anchor is adopted. | Source |
| REGULATORY_EXCLUSIVITY | — | SCOPE_CONTEXT | HISTORICAL_ORIGINAL_ADULT_SCOPE; Diagnostic product remains excluded from therapeutic selection. NCE ends 2013-07-03, based on the original 2008 active-moiety approval, not five years after the 15 mL presentation approval on 2013-02-04. M-155 through 2018-03-27 adds observational pediatric study findings, age greater than 2 months through 18 years, to section 8.4; it is not protection of all adult/pediatric diagnostic use. The latest 2026 label extends pediatric evidence further. No complete later-label anchor or combination is established. | Source |
| REGULATORY_EXCLUSIVITY | — | SCOPE_CONTEXT | PARTIAL_PEDIATRIC_OBSERVATIONAL_DATA; Diagnostic product remains excluded from therapeutic selection. NCE ends 2013-07-03, based on the original 2008 active-moiety approval, not five years after the 15 mL presentation approval on 2013-02-04. M-155 through 2018-03-27 adds observational pediatric study findings, age greater than 2 months through 18 years, to section 8.4; it is not protection of all adult/pediatric diagnostic use. The latest 2026 label extends pediatric evidence further. No complete later-label anchor or combination is established. | Source |
| REGULATORY_STATUS | 2013-02-04 | DECISION_BASIS | DIAGNOSTIC_NONTHERAPEUTIC_PRODUCT; canonical 2013 DEEP_REVIEW; APPROVAL_YEAR_FALLBACK. | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.